顺化:新的分子机制和向性治疗肝脏疾病的前景
Jie Zhou1, Xiaoling Tian2, Yifang Zhou3
1Department of Hepatology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan, China.
Frontiers in molecular biosciences
|March 6, 2026
概括
糖化是一种蛋白质修饰,通过改变新陈代谢功能和免疫反应,在肝脏疾病中起着关键作用. 这篇综述探讨了糖化.
科学领域:
- 生物化学和分子生物学
- 肝病学 肝病学是一种肝病学.
- 后翻译修改 后翻译修改
背景情况:
- 顺化是一种新的翻译后修饰,它涉及将顺基添加到氨酸残留物中,从而改变蛋白质的结构和功能.
- 肝脏是代谢中心,由于其高代谢活性,化会显著影响肝脏.
- 顺化与肝脏代谢功能障碍和疾病进展有关,因为它影响了酶活性,表观遗传学和免疫力.
研究的目的:
- 系统地审查化分子的分子特征和调节网络.
- 分析化在主要肝脏疾病中的机械作用.
- 综合当前的治疗策略,针对肝脏疾病管理的化.
主要方法:
- 关于蛋白质化和肝脏疾病研究的文献综述.
- 对分子机制的分析,将化与代谢功能障碍,表观遗传学和肝脏免疫重塑联系起来.
- 综合治疗方法,包括药物重用,小分子和传统中医药.
主要成果:
- 糖化从根本上改变了蛋白质的结构和功能,特别是在代谢活跃的肝脏中.
- 糖化作为一种病理机制,在肝脏中弥合代谢功能障碍和疾病进展.
- 针对化的治疗策略在肝脏疾病管理方面表现有前途.
结论:
- 化是一种关键的翻译后修改,对肝脏健康和疾病有重大影响.
- 了解化作用为诊断和治疗肝病提供了一个新的框架.
- 向化为肝脏疾病管理提供了有前途的治疗途径.
相关概念视频
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Phase II Reactions: Acetylation Reactions
945
Acetylation, a phase II biotransformation reaction, introduces an acetyl group to drugs or their metabolites. Acetyltransferase enzymes facilitate this reaction, which resembles α-amino acid conjugation due to the addition of a functional group to the drug molecule.
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
The substrates for acetylation are typically drugs or their metabolites with an amino, sulfonamide, or hydrazine functional group. Acetylation can occur at several points in the drug molecule, including primary, secondary, and...
945
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
49
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
49
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
56
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
56
Pharmacogenomics: Identification of New Drug Targets
55
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
55
Targets for Drug Action: Overview
10.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.9K


